-
ABOUT USSSY Group Limited is a large high-tech pharmaceutical enterprise with coordinated development of R&D and industrialization in multiple fields such as new drugs, generic drugs, characteristic APIs
-
INNOVATIONSSY Group Limited has built a relatively perfect scientific research and innovation system with the development mode of “production, learning, research, and application” of multi-disciplinary integration and multi-directional combination.
-
RECRUITIt has established high-level innovation platforms such as engineering laboratory and technology research center jointly with Chinese Academy of Sciences, and now has nearly 400 high-level talents in drug research, analysis and clinical research.
-
SUBSIDIARIESThe company has a diversified business development pattern of R&D, production and export of new drugs, generic drugs, characteristic APIs, advanced finished pharmaceutical products, biological preparations and pharmaceutical packaging materials.
-
CONTACTWe will continue to strengthen innovation-driven development, will vigorously encourage the integration of production and research, strengthen and improve the five domains: new drugs, biological drugs, traditional Chinese medicine, generic drugs and APIs
Leaders of the Shijiazhuang Municipal Bureau of Statistics Conduct a Research Visit to Shijiazhuang Sihua Pharmaceutical
Category:
发布时间：2020-05-07
【概要描述】
On April 28, Luo Jianfang, Deputy Research Fellow at the Shijiazhuang Municipal Bureau of Statistics, led a delegation to Shijiazhuang Sihua Pharmaceutical Co., Ltd. for an on-site inspection of the company’s economic performance. Wang Chunfa, Deputy General Manager of Shijiazhuang Sihua Pharmaceutical, accompanied the delegation.
On April 28, Luo Jianfang, Deputy Research Fellow at the Shijiazhuang Municipal Bureau of Statistics, led a delegation to Shijiazhuang Sihua Pharmaceutical Co., Ltd. for an on-site inspection of the company’s economic performance. Wang Chunfa, Deputy General Manager of Shijiazhuang Sihua Pharmaceutical, accompanied the delegation during the visit.
Wang Chunfa briefed the research team on the company’s current production and operational status. The team commended Shijiazhuang Sihua Pharmaceutical for its efforts in overcoming adverse factors and accelerating corporate development.
The research team pointed out that, due to the impact of the epidemic, all sectors across the city have been affected to varying degrees. It is therefore essential to promptly monitor the resumption of work and production by enterprises, so as to provide a scientific basis for policy-making and to support the city’s economic recovery. The team emphasized that effective epidemic prevention and control, coupled with timely information on the resumption of operations at enterprises and projects, is both a prerequisite and a driving force for ensuring the normal functioning of the economy; that robust economic monitoring, early-warning, and analytical capabilities must be in place to conduct follow-up surveys and analyses of issues and challenges arising from temporary disruptions, thereby providing a comprehensive and timely picture of economic performance; and that national, provincial, and municipal support policies should be fully leveraged, with intensified publicity efforts to ensure their effective implementation, assist enterprises in overcoming difficulties, and bolster economic development.
Keywords:
Recommended News
Share to
SERVICE HOTLINE
Address: Shimen Building, No. 8 Xingye Street, Shijiazhuang Economic and Technological Development Zone
Tel.: +86-311-67167130
Email: office@sjzsiyao.com
Mobile site
E code
Non-Commercial (Filing) – 2025-0091